Skip to main content
Premium Trial:

Request an Annual Quote

Microba, Macrogen Form Microbiome Services Alliance

NEW YORK (GenomeWeb) — Australian biotech firm Microba said today that it has partnered with Macrogen to develop microbiome research services for international markets.

Under the terms of the deal, Microba and Seoul-based Macrogen will initially work together on a shotgun metagenomic sequencing-based service that will be offered in South Korea and other nations outside of Australia. The companies also aim to build a library of high-resolution gut microbiome data that they will use to develop microbiome-based diagnostics and therapeutics.

Additional terms were not disclosed.

"Microba is very pleased to work together with Macrogen, which is well known for its world-class genetics analysis capacity and its vast experience in data analysis," Microba CEO Blake Wills said in a statement. "The two companies will work closely to advance microbiome analysis technology, as well as [launch] various services in the direct-to-consumer, research, and clinical markets."

Last month, Microba announced that it had selected Google Cloud to handle its data and computing needs.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.